Insulin analogues: too much noise about small benefits

Siebenhofer-Kroitzsch, Andrea; Horvath, Karl; Plank, Johannes
February 2009
CMAJ: Canadian Medical Association Journal;2/17/2009, Vol. 180 Issue 4, p369
Academic Journal
The authors reflect on the research findings which demonstrate that insulin analogues are not as effective as conventional insulin in glycemic control. They cite that based on studies conventional insulin still remain effective, thus, extensive promotion for the benefit of insulin analogues are not justified. They remark that budget should be spent more on educational programs in improving the medical outcomes for diabetics, until long-term studies affirm the benefits of insulin analog.


Related Articles

  • Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog. Young, Jason R.; McAdam-Marx, Carrie // Clinical Medicine Insights: Endocrinology & Diabetes;2010, Issue 3, p65 

    Insulin detemir is a long-acting basal insulin approved for use in patients with type 1 (T1DM) or type 2 diabetes (T2DM). Insulin detemir has demonstrated equivalent glycemic control and hypoglycemic risk when compared to insulin glargine, and insulin detemir has generally but not consistently...

  • Mealtime Glucose Regulation With Nateglinide in Healthy Volunteers. Kalbag, Jyoti B.; Walter, Yulia H.; Nedelman, Jerry R.; McLeod, James F. // Diabetes Care;Jan2001, Vol. 24 Issue 1, p73 

    Focuses on a study which compared the pharmacodynamic effects of single doses of nateglinide, repaglinide and placebo on mealtime insulin secretion and glycemic control in healthy subjects. Research design and methods; Results; Conclusions.

  • COMMENTARY: Review: Meglitinide analogues reduce glucose levels in type 2 diabetes, but morbidity and mortality effects are unknown. Ganda, Om P. // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p65 

    The author reflects upon the results of a clinical study on the effectiveness and safety of meglitinide analogues (MA) in the treatment of type 2 diabetes mellitus. He comments that the MAs improved the glycemic control but the efficacy of MAs and sulfonylureas was not compared in the study. He...

  • Intensification of insulin. Hall, Gwen // Practice Nurse;2/26/2010, Vol. 39 Issue 4, p28 

    The article outlines the options for intensification of insulin regimen to achieve glycaemic control. Reference is made to the United Kingdom Prospective Diabetes Study which suggests the need for insulin therapy for type 2 diabetes. A structured program advocated by the National Institute for...

  • Achieving glycemic control with insulin in type 2 diabetes. Bell, David S.; Leahy, John L.; Piziak, Veronica K. // Patient Care for the Nurse Practitioner;Oct2002, Vol. 5 Issue 10, p6 

    The article discusses the use of insulin to achieve glycemic control in type 2 diabetes. When dietary modification, an exercise program, and 2 or 3 oral antidiabetic agents can no longer control the blood glucose level in patients with type 2 diabetes, it is time to consider insulin therapy....

  • Integrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology update. Tumminia, Andrea; Sciacca, Laura; Frittitta, Lucia; Squatrito, Sebastiano; Vigneri, Riccardo; Le Moli, Rosario; Tomaselli, Letizia // Patient Preference & Adherence;Sep2015, Vol. 9, p1263 

    Insulin pump therapy combined with real-time continuous glucose monitoring, known as sensor-augmented pump (SAP) therapy, has been shown to improve metabolic control and to reduce the rate of hypoglycemia in adults with type 1 diabetes compared to multiple daily injections or standard continuous...

  • Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. Perkins, Bruce A.; Cherney, David Z. I.; Soleymanlou, Nima; Lee, Justin A.; Partridge, Helen; Tschirhart, Holly; Zinman, Bernard; Mazze, Roger; Fagan, Nora; Kaspers, Stefan; Woerle, Hans-Juergen; Broedl, Uli C.; Johansen, Odd Erik // PLoS ONE;11/6/2015, Vol. 10 Issue 10, p1 

    Background: We recently reported improved glycemic control with reduced insulin dose in subjects with type 1 diabetes treated with the sodium glucose co-transporter-2 inhibitor empagliflozin. To further characterize the effects, we analyzed diurnal glycemic patterns by continuous glucose...

  • Cotherapy With Recombinant Human Insulin-Like Growth Factor I and Insulin Improves Glycemic Control in Type 1 Diabetes. Thrailkill, Kathryn M.; Quattrin, Teresa; Baker, Lester; Kuntze, Joyce E.; Compton, Peter G.; Martha Jr., Paul M. // Diabetes Care;Apr99, Vol. 22 Issue 4, p585 

    Presents information on a study that analyzed the effects 12 weeks of cotherapy with recombinant human IGF-1 and insulin glycemic control in patients with type 1 diabetes. Research design and methods; Results; Conclusions.

  • Low-Glycemic Index Diets in the Management of Diabetes. Brand-Miller, Jennie; Hayne, Susan; Petocz, Peter; Colagiuri, Stephen // Diabetes Care;Aug2003, Vol. 26 Issue 8, p2261 

    OBJECTIVE — The use of diets with low glycemic index (GI) in the management of diabetes is controversial, with contrasting recommendations around the world. We performed a metaanalysis of randomized controlled trials to determine whether low-GI diets, compared with conventional or high-GI...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics